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The goal of this paper is to present an overview of drug delivery from polymeric
therapeutic lens to the anterior segment of the eye. Mathematical models that describe in
vitro and in vivo drug delivery, from different types of lens, are presented. Healthy and
pathological situations are addressed. Numerical simulations are included and compared
with experimental results.
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Introduction
Controlled drug delivery occurs when a polymer
is combined with a drug in a such a way that the re-
lease profile is predefined. Conventional forms of
drug delivery are based on tablets, eye drops, oint-
ments and intravenous solutions. These delivery sys-
tems were characterized by an immediate and non
controlled kinetics depending essentially on the prop-
erties of tissues to absorb drugs.In the last decades
drug delivery devices have moved to more complex
controlled systems. Advances in polymer science
have led to the development of second generation
drug-delivery systems which purpose is to maintain
drug concentration in the blood or in target tissues at a
desired value and during an extended period of time.
The improvements in the properties of polymers, by
combining different compounds and additives, the use
of biodegradable polymers and the enhancement of
diffusion processes come at the expense of more com-
plex transport phenomena which are known to influ-
ence drug delivery rates.1,2 The urgency for mathe-
matical models in the area and the necessity for a pre-
dictive environment, avoiding costly in vitro experi-
ments, become all the more relevant in light of the
heightened focus on polymer-based drug-delivery de-
vices. Also future drug delivery modelling work
should consider drug transport in target tissues after
its release from polymeric devices.
Efficient drug delivery to the eye is becoming
increasingly vital with the development of new de-
vices and the increasing prevalence of eye diseases,
accompanying population ageing. In this paper we
will present an overview of drug delivery from ther-
apeutic lens to the anterior segment of the eye. The
platforms we analyse and the models we present to
simulate the drug release can be easily adapted to
the case of transdermal drug delivery systems.
The eye is anatomically divided into the anterior
and posterior segments with the lens-iris barrier
roughly demarcating the two segments. For both the
anterior and the posterior segment of the eye, topical
route is very inefficient in delivering therapeutic
concentrations because of drainage through the
naso-lacrimal ducts, low permeability of corneal epi-
thelium, systemic absorption and the blood aqueous
barrier. According to these facts it is estimated that
when a drop is instilled into the eye it is diluted by
the lacrimal secretion and 95% is cleared by the tear
fluid. To avoid drug loss, side effects and also to im-
prove the efficiency of drug delivery, many research-
ers have proposed the use of therapeutic contact
lenses as a vehicle to deliver ophthalmic drugs. The
main advantage of this method is the possibility of
controlling the drug delivery by means of the use of
polymeric matrices designed to achieve pre-defined
performances as well as their high degree of comfort
and biocompatibility. Several techniques have been
proposed in the literature. Without being exhaustive
we can mention the use of
(i) soaked simple contact lenses;3–5
(ii) compound contact lenses with a hollow
cavity;6
(iii) entrapment of drugs by polymerization of
hydrogel monomers in the presence of species to be
entrapped or by direct dissolution;7–14
(iv) biodegradable contact lenses.15
The use of soaked simple lens is more efficient
than the use of ophthalmic drops but the drug load-
ing is very limited and the delivery period of time is
very short. In the case of lens with an hollow cavity
it has been observed that the oxygen and carbon di-
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oxide permeability is lower than the prescribed for
a safe daily use. In the first of such papers the en-
trapment of the drug is achieved by polymerization
of monomers and by encapsulation of drug within
particles dispersed in the lens.8,9 The nanoparticles
are formed by polymerization, during or after which
the drug is added, leading to covalent drug binding
to the polymer. This binding of the drug depends on
its physicochemical properties as well as the nature
of the polymer. In the case of encapsulation in par-
ticles the drug to be delivered must overcome two
barriers: the diffusion in the particles and the diffu-
sion in the polymeric matrix. As a consequence the
drug release attains in this case several days. The
main difference between the two types of lens pro-
posed 8,10 lies in the polymers used. In the first of
such papers the polymeric matrix was made from a
p-HEMA (Monomer 2-hydroxyethyl methacrylate)
gel and the particles were stabilized with a silica
shell; in the second of the previously mentioned pa-
pers the film was prepared using p-HEMA/MAA
(Copolymer 2-hydroxyethyl methacrylate co-metha-
crylic acid) and silicone particles have been used.
In the first case there is a delay period between
the delivery from the polymeric matrix and from
the particles. It can attain three or four days
and during this period there is practically no drug
delivery. In the second case the drug is continu-
ously delivered with no pause period during the
release.
At the best of our knowledge the more recent
type of therapeutic lens has been proposed by a
team of Harvard Medical School.15 The idea under-
lying the mechanism used to induce a delay in the
drug delivery is to use a sandwich type structure
composed by three polymeric layers as represented
in Figure 1: two non biodegradable layers (HEMA)
coating a biodegradable PLGA (copolymer poly
lactic co-glycolic acid) film containing drug. Nu-
merical simulations of drug delivery from the lens
with particles entrapping drug10 and the sandwich
lens15 have been compared in a recent paper.16 Ac-
cording to the numerical simulations presented
there and to in vitro experiments15 the release from
the "sandwich lens" is slower than the release from
therapeutic lens presented with particles entrapping
drug,8,10 lasting for thirty days.
From a medical point of view, the central ques-
tion is to have a prediction of the drug concentration
in the anterior chamber of the eye. In this case mathe-
matical models are the only available tool to make
such prediction. Several mathematical models de-
scribing the behaviour of drug concentration across
the cornea when a drop is instilled can be found in the
literature.17–19 Nevertheless, when the drug is deliv-
ered from a contact lens the concentration and mass
profiles across the cornea are qualitatively different as
predicted by a mathematical model that simulates the
concentration in the anterior chamber when the drug
is delivered from a therapeutic contact lens, where the
drug is dispersed in the polymeric matrix and encap-
sulated in nanoparticles.11 A comparison with the be-
havior of concentration plots in the anterior chamber,
in the case of topical drug administration, shows the
efficiency of controlled drug delivery.
Therapeutic lens are essentially used in the
case of severe diseases as glaucoma, for which long
periods of drug delivery, from one week to a month,
are needed. Glaucoma is related with a buildup of
intraocular pressure (I.O.P.) due to an obstruction of
Schlemm canals or an excessive production of
aqueous humor (Figure 2). When the delivery in the
anterior chamber is modelled by an ordinary differ-
ential equation, its anatomy is not taken into ac-
count.11 To obtain a more realistic description of the
delivery, the I.O.P. and the physio-pathological
characteristics of the anterior chamber should be
considered. To describe the in vivo delivery a math-
ematical model which consists of three coupled sys-
tems linked by interface conditions was considered:
drug delivery from a therapeutic lens, diffusion and
metabolic consumption in the cornea, diffusion,
convection and metabolic consumption in the ante-
rior chamber of the eye. Numerical simulations in
healthy and pathological conditions can be of great
help to ophthalmologists and to material scientists
because they give indications of how to tailor poly-
meric lens to fit specific patient's needs.20
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F i g . 1 – Examples of single and multilayer drug delivery
systems
F i g . 2 – Anatomy of the eye
(http://www.blackwelleyesight.com/narrated-eye-exam/)
We present two mathematical models that sim-
ulate in vitro drug delivery from the two different
lenses.10,15 Comparisons with laboratorial experi-
ments are also presented. For the lens with particles
a time constant which represents the mean time to
achieve equilibrium – effective time21,22 – is com-
puted. A mathematical model that simulates in vivo
drug delivery to the anterior chamber from a thera-
peutic lens is also presented.20 Numerical simula-
tions in healthy and pathological conditions are
analysed. Finaly some conclusions are addressed.
Simulating in vitro drug release
from therapeutic lens
In this Section we will focus mainly on two
types of therapeutic lens: lens with dispersed parti-
cles encapsulating drug and sandwich type lens.10,15
Lens with particles
Mathematical model and laboratorial experiments
The lens is a p-HEMA/MAA platform with flur-
biprofen dispersed and entrapping particles filled with
drug.10 The copolymers with drug incorporated in the
polymeric matrix were synthesized by dissolving
flurbiprofen directly into the mixture of monomers
and adding a microemulsion containing silicone parti-
cles encapsulating drug. The solution was injected into
a mold, constituted by two glass plates coated with
teflon. The polymerization reaction was performed at
60 °C during 24 hours. The obtained copolymer was
cut into circular samples with 1 cm of diameter.
In Figure 3 we present a SEM (scanning elec-
tron microscopy) micrograph of a copolymer with
drug dispersed and particles encapsulating drug.10
The mathematical model used to simulate in vi-
tro drug delivery (when the lens has a width of 2l
and is completely immersed in water) which we de-
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where Cg represents the drug concentration in the
gel, Cb the drug concentration in the particles, D the
diffusion coefficient of the drug in the gel and 
stands for the product of the mass transfer coefficient
for drug transport across the particle surface and the
ratio between the surface and the volume of parti-
cles. We note that no diffusion was considered in the
second equation in (1). The second equation in (1) is
a good approximation of drug release from particles
to the gel provided that the typical dimension of par-
ticles is small when compared with the size of lens.
In this sense particles are looked as having no di-
mension, acting as immobilizing sites, and drug as
having two states: free (Cg) and bound (Cb). We note
that – except for what concerns Figures 12 and 13 –
the units in the paper are presented in Annex A. The
reason for such exception lies in the fact that the ex-
perimental plots exhibited in these Figures were in
different units in the paper where a sandwich lens
was first described.15



















where C0g is the initial concentration in the gel and
the C0b the initial concentration inside the particles,
and the boundary conditions
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with CE representing an external concentration.
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can be considered, where 1 stands for a transference
coefficient. We note that (4) is a more realistic de-
scription of the clearance mechanisms, meaning that
the drug flux at the boundary of the lens is propor-
tional to the difference between the drug concentra-
tion in the exterior region and the drug concentration
at the lens surface. Conditions (3) mean that the drug
is immediately removed and the external drug con-
centration is constant. To simulate in laboratory this
behaviour the concentration of drug in water is kept
constant by means of a renewal mechanism that
takes place at fixed intervals of time.
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F i g . 3 – SEM image of the cross section of a copolymer
with particles
To have a clear picture of the delay effect of par-
ticles different scenario were considered (Table 1).
System 3 represents the lens with entrapped
particles.10 System 4 describes an academic situa-
tion used to test the robustness of the model.
Using CE = 0 and the information in Table 1, it
can be proved analytically, from (5) that for any
choice of the parameters
M t M t M t M t t2 3 4 1 0( ) ( ) ( ) ( ), ,    (6)
where Mi, i = 1,2,3,4 represent the mass delivered
from Systems 1, 2, 3 and 4 respectively. In Figure 4
we exhibit plots computed from the analytical
solution (5) considering one hundred terms. We
took C0b = 0.5 for M2(t) and C
0g = 0.5 for M1(t) and
M4(t). For M3(t) we considered C
0g = C0b = 0.25. We
note that the values of the parameters used in the
simulations of Figure 4 are not physical.
In Figure 5 we exhibit experimental release
profiles of flurbiprofen for Systems 1, 2 and 3 (S1,
S2, S3). At this point we just want to underline the
qualitative agrement between numerical results in
Figure 4 and experimental results in Figure 5. In
what follows physical parameters will be consid-
ered in the simulations.
Mean time to achieve equilibrium:
effective time constant
To improve the design of the lens it is
important to know the waiting time that is the
period of time elapsed before the mass attains
a certain therapeutic level and how to adjust the
parameters to produce a pre-defined delivery
profile. In this subsection we compute the effective
time.21





lim ( ). The effective time teff is defined
as the mean time to achieve the equilibrium,
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Due to the linearity of (1) an exact solution for the total released mass M(t) can be computed. Using for a
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matrix with dispersed drug
matrix with silicone particles
encapsulating drug
matrix with dispersed drug
and entrapped in particles
matrix with dispersed drug
and void particles at t = 0
C b0 0 0 , 
C
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C Cb
g0 0 0 , 
C b0 0 0 , 
F i g . 4 – Delay effect on the drug release of the particles
for Systems 1, 2, 3 and 4
F i g . 5 – Experimental release profiles of flurbiprofen for
three different platforms
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To compute teff only M p( ), the Laplace trans-
form of M(t), must be known. In fact it can be
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In the case of System 1 ( = 0, C0b = 0), effec-
tive time can not be obtained from (10). A direct








In Figure 6 plots of teff given by (10), as a
function of  and D, are exhibited with C0g = 0.5,
C0b = 0.25, CE = 0, l = 1. As expected effective time
is a decreasing function of D, for constant , and a
decreasing function of , for constant D. In fact
when D increases the drug diffuses faster; when 
increases the drug encapsulated in the particles
easier surmounts the barrier represented by their
boundary. We note that the influence of D is more
significant than the influence of .
In engineering literature22,23 it is generally ac-
cepted that the onset of equilibria is defined by the
response time tr, where tr = 4teff.
If we compute 4teff for the previous systems,
for D = 0.05, l = 1,  = 0.05, C0g = 0.5, C0b = 0.5,
CE = 0, we obtain the values presented in Table 2.
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F i g . 6 – Behavior of teff as a function of  (left) and D
(right)
T a b l e 2 – Response times of model I
System 1 System 2 System 3 System 4
4teff 32 121.6 116.5716 104
We note that t t t tr r r r
1 4 3 2   , where the su-
perscript refers to the systems. This result agrees
with the inequalities established in (6) for the deliv-
ered masses. In fact as M2(t) < M3(t) than the steady
state of System 2 is reached after the steady state of
System 3, that is t tr r
3 2 .We observe that System 2
induces the largest delay. However it can not be
used as a platform of drug delivery because the
loading of particles still presents many laboratorial
problems.
Interpreting t as a statistical variable, with ex-
ponential density distribution d *(t), the probability
that t kt P t kteff eff , ( ), is defined, for every
k  , by
P t kt eeff
k( ) .   1
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where Mest(t) represents an estimation for M(t).
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An estimation Mest(t) for the mass delivered
during [0, t], is defined by23
M t l e C C Cest
t
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We observe that this estimation avoids the nu-
merical solution of (1). It can be used with (10) as a
simple tool to estimate the mass released until a cer-
tain time.
In Table 3 the estimated masses for several
times t, computed using (13), are presented.
In Table 4 are presented the estimated delivered
masses Mest(t), (15), and M3(t), (5), computed with
D = 0.05, l = 1,  = 0.05, C0g = 0.5, C0b = 0.5, CE = 0.
The plots of the released mass M3(t) and the
corresponding estimated mass Mest(t) for the param-
eters in Table 4, are represented in Figure 7. The
values of M3(t) have been computed from (5) with
100 terms. As expected when t increases a better
approximation Mest(t) of M3(t) is obtained.
Once fixed a certain therapeutic mass and a
certain waiting time to reach this mass, the lens can
be tailored in order to fullfil these requirements. Let
us consider, for example, that D and C0g are free pa-
rameters. If we define that at teff = 1000, the re-
leased mass should be Mest(4teff) = 1, then
C0g = 0.484329, D = 8.415 × 10–3,
where C0b = 0.025, CE = 0, l = 1,  = 0.01. If the
same therapeutic mass is to be delivered within a
shorter period of time, teff = 100, then as expected
the diffusion coefficient increases, obtaining in this
case D = 1.774 x 10-2. The change in drug delivery
coefficient can be achieved by manipulating the
polymer structure.
Numerical simulations versus experimental results
To manipulate analytically the equations in
model (1) the diffusion coefficient was considered
constant. As suggested by laboratorial experiments
a more realistic model must include the concentra-
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T a b l e 4 – Estimated mass and total delivered mass for the
therapeutical lens (Model I – System 3) (D = 0.05,
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F i g . 7 – Mass tracking of M3(t), for parameters in Table 3
tion dependence of the diffusion coefficient D, rep-
resented through a time dependence.
In Figure 8 we present the numerical released
masses from System 3 – the lens with particles –
and the experimental masses for the first eight
hours. In the computations the following values of
the parameters were considered:
C0b = 0.05102, C0g = 0.28,
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In Figure 9 we plot the results obtained from
System 3 using experimental values and numerical
simulations for a period of eight days, where the
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We note that expressions (17) and (18) corre-
spond to diffusion coefficients measured in labora-
tory. To represent more realistically the exterior con-
centration we defined CE(t) = !1u(–l, t) with !1 = 0.5.
A sandwich type lens
A different mechanism to induce delay in drug
delivery from therapeutic lenses is to entrap the
drug between polymeric layers.15 The idea lies in
creating sandwich type structures composed by
three polymeric layers as represented in Figure 1:
two non biodegradable layers (HEMA) coating a
biodegradable PLGA film containing drug (Model
II). As no analytical manipulations were carried on,
diffusion coefficients have been represented by
more realistically non linear functions.
Mathematical models
The behavior of the drug release is modeled by
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F i g . 8 – Numerical (M3,n) and experimental (M3,e) mass de-
livered from a lens with dispersed drug and en-
trapped particles loaded with drug (System 3)
during the first 8 hours
F i g . 9 – Comparison of delivered numerical (M3,n) and ex-
perimental (M3,e) masses for System 3









In (19)-(21) C1 and C2 represent the drug
concentration in the non biodegradable layers, C0
represent the drug concentration in the bio-
degradable PLGA film, D1e and D2e stand for the
initial diffusion coefficients in HEMA and PLGA,
respectively. We note that li are the thicknesses of
the different layers, C 0
0 and c0 are the free and
bound initial concentrations in PLGA, respectively.
Parameters  and " are related with the flux condi-
tions at the boundary and at the interfaces, respec-
tively; "1 and "2 are positive parameters. We as-
sume that binding is not significant in HEMA lay-
ers. We observe that in equation (20) the source
term c e t0!
! represents the contribution of bound
drug as PLGA film degradates. Such term is pro-
portional to the initial concentration of bound drug
with a time dependent degradation rate represented
by ! !e t .
Experiments carried with different types of
sandwich structure: two HEMA layers linked by a
void space containing drug (Model III) have also
been described.15 The kinetics of the release can be
described by equations (19), (21) and an evolution























































where Cvs represents the drug concentration in the
void space, C vs0 the initial concentration and e = l2 – l1
stands for thickness of the void space between the
two HEMA layers.
In Table 5 we present the description of the
three types of lens we have mentioned so far.
We note that model I (System 3) corresponds
to the lens described in section 2.1. We present
in Figure 10 the plots of the total released masses,
corresponding to models I, II and III with bound-
ary conditions of type (4) that simulate in vitro re-
sults.
We considered CE = 0,  = 0.01, in all simula-
tions and the values of the parameters exhibited in
Table 6. If the drug is entrapped in a single non bio-
degradable layer where particles are dispersed
(model I – System 3) the release is faster than in
models II and III in a first period. Afterwards the
plot corresponding to model III cross the plot of
model I. We remark that “sandwich platforms” with
a biodegradable layer – model II – lead to a slower
drug release than “non sandwich platforms” –
model I.
In Figure 11-up- we plot the total released mass
of model II for two different degradation coeffi-
cients, and in Figure 11-down- we illustrate the be-
haviour of released mass for different free and
bound initial concentration. In these simulations the
following values were used: CE = 0, D1e = 0.001,
D2e = 0.02,  = 0.01, "1 = 0.02, "2 = 0.02, l1 = l2 = l3 = 1.
From the figure in the top we conclude that the de-
livered mass is an increasing function of !. In fact
as the polymer erodes the bound drug is free to dif-
fuse through the HEMA layers and the largest is the
degradation rate the fastest is the release. The influ-
ence of initial concentration is also illustrated in the
bottom of Figure 11: for each t the total released
mass is a decreasing function of the initial bound
mass. We observe that the values used for the pa-
rameters do not correspond to physical values.
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T a b l e 5 – Description of the models







Lens of "sandwich" type
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F i g . 1 0 – Comparison of Models I, II and III





D = 0.005,  = 0.05, C0b = 0.01, C0g = 0.04, l = 1
D1e = 0.005, D2e = 0.03, "1 = 0.002, "2 = 0.001,
! = 0.01, c0 = 0.01, C0
0 = 0.09, l1 = l2 = l3 = 1
D1e = 0.005, "1 = 0.002, C
vs
0 = 0.1, l1 = l3 = 1
Numerical simulations versus experimental results
We compare now the numerical simulations
obtained with model II with experimental results
concerning the sandwich type lens under study. For
this reason the mass units in this subsection are mg,
as in the referred experimental paper.15
In Figure 12 numerical simulations of model II
are compared with laboratorial results. We consider
CE = 0, D1e = 0.8554, D2e = 4.2336 x 10
-7,  = 0.5,
"1 = 1.5, "2 = 0.1, ! = 0.0714, c0 = 0.03475, C 0
0 = 0.1,
l1 = 0.02, l2 = 0.01, l3 = 0.02. The lens is still releas-
ing drug after 30 days.13 The qualitative behaviour
of the numerical prediction shows a good agree-
ment after day 5. We note that the experimental re-
sults exhibit an initial burst that is not present in the
numerical solution. This is a point deserving some
attention. In fact if there was no drug at all in the
HEMA layers as reported in 13 this initial burst
would not be expectable. This argument suggests
that the non biodegradable layers are not completely
drug free. In fact, if we consider that C1(x, 0)  0,
x  (0, l1) and C2(x, 0)  0, x  (l2, l3) we obtain
the result presented in Figure 13, where a numerical
initial burst, agreeing with experimental results, is
now observed.
Simulating in vivo drug release
from therapeutic lens
To have a prediction of the drug concentration
in the anterior chamber of the eye we couple the
systems representing the delivery from a therapeu-
tic lens with the uptake in living tissues.
The eye is divided into anterior and posterior
chamber (Figure 2). The anterior chamber is the
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F i g . 1 1 – A comparison of released mass from the “sand-
wich” lens (model II) for two different degradation coefficients
 (with c0 = 0.3, C0
0 = 0.7) -up- and different free and bound
initial concentration -down- (with  = 0.1)
F i g . 1 2 – Comparison of delivered numerical and experi-
mental masses for "sandwich" type lens (model
II)
F i g . 1 3 – Comparison of delivered numerical and experi-
mental masses for "sandwich" type lens (model
II)
front portion of the eye containing aqueous fluid. It
is bounded in front by the cornea and in the back by
the iris and the lens. The posterior chamber is the
space behind the iris, lens and ciliary body. In what
follows the release from a therapeutic lens is com-
pared with the behaviour of an instilled drop. The
anatomy of the anterior chamber is included in the
model and a pathological situation – the obstruction
of Schlemm canals – is analyzed.
Diffusion in the cornea and anterior camera:
therapeutic lens versus topical drops
We consider now the coupling of equations
representing the diffusion in the lens, in the cornea
and the evolution in the anterior chamber. In this
model it is assumed that there is no convection of
the aqueous humor. To model the diffusion of drug
from a therapeutic lens through the cornea to the
anterior chamber we consider equations (1) with D
= Dg, in the domain (– l1, 0).
The behavior of the drug concentration in the
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where Dc stands for the diffusion coefficient in the
cornea and Kc represents a coefficient that takes
into account the metabolic consumption.
The conservation of drug in the anterior cham-
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where Ac is the surface area of the cornea, fc repre-
sents the fraction of Ac occupied by the diffusional
route considered and Va is the distribution volume
of solute in the anterior chamber.
Equations (1), (23) and (24) are coupled with
the initial conditions
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In (29) fg represents the fraction of the lens sur-
face Ag that is occupied by the diffusional route.
The constant Kg,c (30) represents the quotient of
the distribution coefficient in the lens and the cor-
nea and the parameter Kc,a represents a volumetric
rate.
The dependence of Ca on the diffusion coeffi-
cient of the drug in the therapeutic lens is illustrated
in Figure 14-up. As the drug diffusion coefficient in
the lens increases, an increasing of the drug concen-
tration in the anterior chamber is observed as ex-
pected.
An increasing of the drug clearance in the ante-
rior chamber produces a decreasing of the drug
concentration in this compartment. This behavior is
illustrated in Figure 14-down.
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F i g . 1 4 – Drug concentration in the anterior chamber Ca
for different values of the diffusion coefficient in the lens
(down) and for different values of the clearance in the anterior
chamber (up).
To compare the efficiency of therapeutic lens
with topical eye drops we replaced the delivery

























where Cf denotes the drug concentration in the tear
film and S represents a (fixed) lacrimal secretion
rate. In (32) kd denotes the drainage constant, VL
and Vi represent the normal lacrimal volume and the
initial tear volume after an instillation of drug. The
previous equation is coupled with the differential
equations (2), (3), initial conditions (26), (27),
C Cf f( ) ,0
0 (33)
and with the boundary condition (31). The same as-
sumption is considered in the mathematical model
of topical administrations in some works found in
the literature.17,18 The coupling between the drug
evolution in the tear film and in the cornea is de-
fined by
  D f A
C
x





( , ) ( ( ) ( , )).,0 0 (34)
In Figure 15 we plot the time evolution of
drug concentration in the anterior chamber when a
drop (C drop
a ) and a lens (C lens
a ) are used in drug ad-
ministration. In the computation of C tdrop
a ( ) the fol-
lowing parameters
kd = 1.45, C f
0 = 0.5 x 10-3, VL = 7,
Vi = 10, S = 1.2
are used.17,18
From Figure 15 we conclude that the use of
therapeutic lens leads to a higher concentration of
the drug in the anterior chamber during a larger pe-
riod of time than topical administrations. We ob-
serve that whereas using a therapeutic lens the drug
concentration is significant after 8 hours, when a
drop is instilled in the eye the drug concentration
vanishes after some minutes.
Convective flow in the anterior chamber
of the eye
In this section we describe very briefly the re-
lease of drug from a therapeutic lens, considering
the convection of aqueous humour in the anterior
chamber.20 The anterior chamber is modeled using
real dimensions. The domain is divided into three
subdomains (see Figure 16): the therapeutic lens,
*1, where equations (1) hold; the cornea, *2, where
the drug concentration is described by (23); and the














a  + ,

, *3 , t  0,
is coupled with Navier Stokes equations. Initial, in-
terface and boundary conditions complete the
model. In (35) Da denote the diffusion coefficient
in the anterior chamber,

v the velocity of the
aqueous humour, , the Laplace operator and +
the gradient operator. As mentioned before the
use of therapeutic lens is particulary important in
the case of severe diseases characterized by high
I.O.P.. The intraocular pressure can be explained by
obstruction of Schlemm canals, (see Figure 2 and
Figure 16) or high rates of aqueous humor produc-
tion.
To simulate a pathological situation we con-
sider a geometry with obstructed Schlemm canals.
In our simulations this obstruction induces a high
I.O.P. of mean value 30 mmHg, whereas a normal
value lies in the interval [15,20]. To simulate the
aqueous humour we considered an incompressible
fluid (+

v = 0) and we used the density and viscosity
of water.
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F i g . 1 5 – Evolution of the drug concentration in the ante-
rior chamber when a drop (Cdrop
a ) and a lenses (Clens
a ) are used
in the eye drug administration
F i g . 1 6 – Geometry of the therapeutical lens, cornea and
anterior chamber
In order to illustrate the evolution of drug
concentration, we plot in Figure 17 its value at
t = 20 min in (top) and at t = 2 hour in (down). Two
types of gray scales have been used: a scale in the
left for the concentration of drug in the lens and
cornea and a scale in the right to represent the drug
concentration in the anterior chamber. We note that,
as defined in the scale, the lowest levels of drug
concentration correspond to dark gray. When we
compare these plots we can see that, as expected,
the drug concentration decreases with time.
In Figure 18 we want to illustrate the influence
of the production rate of the aqueous humour in the
behaviour of drug concentration. We represent the
drug concentration at t = 1 h, in the pathological
situation described before; in Figure 18 – top – a
normal rate was considered whereas in Figure 18 –
down – the rate was doubled. We note that the
increase in rate not only increases the I.O.P.
(27,48 mmHg to 40,39 mmHg) but also leads to lowest
values in drug concentration (see scale in Figure 18).
Conclusion
We presented in this paper an overview of con-
trolled drug delivery from therapeutic lens to the
anterior chamber of the eye. Mathematical models
for in vitro delivery of different therapeutic lens
were considered and numerical simulations were
compared with laboratorial experiments. A time
constant -effective time- was introduced and it was
shown how it can be used as a tool to help in the
design of therapeutic lens with predefined delivery
profiles.
Mathematical models that represent in vivo de-
livery have also been considered. The effectiveness
of controlled drug administration versus topical
drops has been established.
To model pathologic situations – as the
obstruction of Schlemm canals or an increase
in the rate of production of aqueous humour –
a more complex model20 is introduced.
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F i g . 1 7 – Drug concentration at t = 20min – (top) and
t = 2 h – (down)
F i g . 1 8 – Influence of the production rate on the distribu-
tion of drug concentration at t = 1 h
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S y m b o l
D  diffusion coefficient of the drug in the polymeric
matrix (cm2/min)
Dc  diffusion coefficient in the cornea (cm
2/min)
Da  diffusion coefficient in the anterior chamber
(cm2/min)
Cg  drug concentration in the gel (g/cm3)
Cb  drug concentration in the particles (g/cm3)
  transfer coefficient (mm–1)
C0g  initial concentration in the gel (g/cm3)
C0g  initial concentration in the particles (g/cm3)
CE  external concentration (g/cm3)
1  transference coefficient (cm/min)
M  exact solution for the total released mass (g)
Mi, i = 1,2,3,4  represent the delivery mass for the
Systems 1, 2, 3 and 4 (g)
M3,n, M3,e  delivered numerical and experimental
masses for System 3 (g)
!1  rates distribution
C1, C2  drug concentration in the non biodegradable
layers (g/cm3)
C0  drug concentration in the biodegradable layer
(g/cm3)
D1e, D2e initial diffusion coefficients in HEMA and
PLGA (cm2/min)
li, i = 1,2,3 thicknesses of the different layers (mm)
C c0
0
0,  free and bound initial concentrations in PLGA
(g/cm3)
, ", "1, "2  positive parameters
Cvs  the drug concentration in the void space in sand-
wich platform (g/cm3)
Cvs0  the initial concentration in the void space (g/cm
3)
Cc  drug concentration in the cornea (g/cm3)
Ca  drug concentration in the anterior chamber (g/cm3)
Kg,c  quotient of the distribution coefficient in the lens
and the cornea
Kc,a  volumetric rate (cm
3/min)
Kc  metabolic consumption drug coefficient in the
cornea
l2  cornea thickness (mm)
Va  distribution volume of solute in the anterior
chamber (l)
Cla  clearance in the anterior chamber (l/min)
Ac  surface area of the cornea (cm
2)
fc  fraction of the cornea surface occupied by the
diffusional route
Cf  drug concentration in the tear film (g/cm
3)
S  lacrimal secretion rate (l/min)
kd  drainage constant (min
–1)
VL  normal lacrimal volume in tear film (l)
Vi  initial tear volume after an instillation of drug
(l)
Cdrop
a  drug concentration in the anterior chamber when
a drop is used (g/cm3)
Clens
a  drug concentration in the anterior chamber when
a lens is used (g/cm3)
v  velocity of the aqueous humour (mm/s)
Mest(t)  estimated mass for M(t)
teff  effective time
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